New study tracks how a common heart valve performs in people born with a bicuspid valve
NCT ID NCT03495050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 150 people with bicuspid aortic stenosis—a narrowed heart valve present from birth—who receive a transcatheter aortic valve replacement (TAVI) using the Evolut Pro or Evolut R XL device. Researchers will measure how well the valve works over time, including blood flow and any leakage. The goal is to see if this less-invasive procedure is safe and effective for this specific group of patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Evolut Pro/XL transcatheter aortic valve
What this could lead to
If successful, this study could confirm that the Evolut valve works well for people with bicuspid aortic stenosis, expanding treatment options for this common heart condition.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove the valve is better than alternatives. Results may not apply to all patients with bicuspid valves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BICUSPID AORTIC VALVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinique Pasteur
Toulouse, Occitanie, 31076, France